No. J0897 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code.

What NDCs are billed under J0897?

CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 4 NDCs under J0897, for Prolia and Xgeva. The table on this page shows each one with its billing units per package.

What is the Medicare payment limit for J0897?

$29.856 per 1 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.

What is one billing unit of J0897?

One unit of J0897 is 1 mg, as stated in the code's descriptor. Units to report = dose given ÷ 1 mg.

J0897 J-Code: Prolia, Xgeva (denosumab)

In short

J0897 is the HCPCS Level II code for injection, denosumab, 1 mg. CMS assigns NDCs for Prolia and Xgeva to it. One billing unit is 1 mg. The Medicare Part B payment limit is $29.856 per unit (October 1, 2026 through December 31, 2026).

Code

Med-Code curated

HCPCS codeJ0897

Billing unit1 mg

Descriptor: Injection, denosumab, 1 mg
Code set: HCPCS Level II, maintained by CMS
Category: Bone Health / RANKL

Medicare Part B payment limit

CMS ASP file

Payment limit per unit$29.856

Per1 mg

Coinsurance17.885%

Effective October 1, 2026 through December 31, 2026. Payment allowance limits subject to the ASP methodology are based on 2Q26 ASP data. CMS note: Inflation-adjusted coinsurance. A payment limit is not a coverage decision; the Medicare contractor decides coverage. CMS ASP pricing files

Units and claim line

Units = dose given ÷ 1 mg. For example, 100 mg is 100 units. Enter the dose to get the units and the NDC line for the CMS-1500 and the 837P.

Dose given (mg)

HCPCS units (1 unit = 1 mg)

Modifier

NDC (11-digit)

NDC unit qualifier

NDC quantity

Enter the dose given to build the claim line.

Drugs mapped to J0897

FDA-listed products billed under J0897

Finished products in the FDA NDC Directory whose brand or single active ingredient, and route, match this code’s entry.

NDC products matching J0897
Product	Strength	Form · route	Labeler	Product NDC
Osvyrtidenosumab-desu	Denosumab 60 mg/mL	InjectionSubcutaneous	Accord BioPharma Inc.	69448-021
Jubereqdenosumab-desu	Denosumab 70 mg/mL	InjectionSubcutaneous	Accord BioPharma Inc.	69448-022
Stoboclodenosumab-bmwo	Denosumab 60 mg/mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-037
Osenveltdenosumab-bmwo	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-038
Denosumab-BMWO	Denosumab 60 mg/mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-058
Denosumab-BMWO	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	CELLTRION USA, Inc.	72606-059
Enobydenosumab-qbde	Denosumab 60 mg/mL	InjectionSubcutaneous	Hikma Pharmaceuticals USA Inc.	0143-9165
Xtrenbodenosumab-qbde	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	Hikma Pharmaceuticals USA Inc.	0143-9166
Bildyosdenosumab	Denosumab 60 mg/mL	Injection, SolutionSubcutaneous	Organon LLC	78206-193
Bilprevdadenosumab	Denosumab 120 mg/1.7mL	Injection, SolutionSubcutaneous	Organon LLC	78206-195
Conexxencedenosumab	Denosumab 60 mg/mL	InjectionSubcutaneous	Fresenius Kabi USA, LLC	65219-668
Bomyntradenosumab	Denosumab 70 mg/mL	InjectionSubcutaneous	Fresenius Kabi USA, LLC	65219-670
Bomyntradenosumab	Denosumab 70 mg/mL	InjectionSubcutaneous	Fresenius Kabi USA, LLC	65219-672
Xgevadenosumab	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	Amgen, Inc	55513-730
Wyostdenosumab	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	Sandoz Inc	61314-228
Proliadenosumab	Denosumab 60 mg/mL	InjectionSubcutaneous	Amgen, Inc	55513-710
Jubbontidenosumab	Denosumab 60 mg/mL	InjectionSubcutaneous	Sandoz Inc	61314-240
Bosayadenosumab-kyqq	Denosumab 60 mg/mL	InjectionSubcutaneous	Biocon Biologics Inc.	83257-029
Aukelsodenosumab-kyqq	Denosumab 120 mg/1.7mL	InjectionSubcutaneous	Biocon Biologics Inc.	83257-030
Oziltusdenosumab-mobz	Denosumab 70 mg/mL	Injection, SolutionSubcutaneous	Amneal Pharmaceuticals LLC	70121-2701
Boncresadenosumab-mobz	Denosumab 60 mg/mL	Injection, SolutionSubcutaneous	Amneal Pharmaceuticals LLC	70121-2702
Ospomyvdenosumab	Denosumab 60 mg/mL	Injection, SolutionSubcutaneous	Cordavis Limited	83457-012

All NDCs for these drugs

NDCs billed under J0897

CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 4 NDCs to J0897 for Prolia and Xgeva. Billing units per package are CMS’s figures for this code’s unit.

NDCs assigned to J0897 in the CMS ASP crosswalk
Drug	NDC (11-digit)	Labeler	Package	Billing units per package
Prolia	55513-0710-01	Amgen Inc	1	60
Prolia	55513-0710-21	Amgen Inc	1	60
Xgeva	55513-0730-01	Amgen Inc	1	120
Xgeva	55513-0730-21	Amgen Inc	1.7	120

J0897: common questions

Is J0897 a CPT code?: No. J0897 is a HCPCS Level II code, maintained by CMS, that identifies the drug supplied. CPT codes are five-digit numbers from the AMA that describe services. Giving the drug, for example an injection or infusion, is usually reported with a separate CPT administration code. CPT codes for drug administration.
What NDCs are billed under J0897?: CMS's ASP crosswalk for October 1, 2026 through December 31, 2026 lists 4 NDCs under J0897, for Prolia and Xgeva. The table on this page shows each one with its billing units per package.
What is the Medicare payment limit for J0897?: $29.856 per 1 mg, effective October 1, 2026 through December 31, 2026, from CMS's Part B drug payment limit file. Multiply by the units billed for the allowed amount before deductible and coinsurance. It is not a coverage decision.
What is one billing unit of J0897?: One unit of J0897 is 1 mg, as stated in the code's descriptor. Units to report = dose given ÷ 1 mg. J-code billing units.

J0897 — Injection, denosumab, 1 mg